Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically validated ADC targets and arming them either with warheads from our proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target.
Recognising the exciting potential of ADCs, Pheon has built a world class leadership team focused on transitioning its lead asset into clinical development. In parallel, it is developing and building a proprietary pipeline of follow-on ADCs to address the unmet medical need of novel targets in hard-to-treat solid tumors across multiple cancer types.
Backed by expert, specialist healthcare investors, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise.
